How Flunisolide Works for Asthma and Nasal Allergies

Flunisolide is a synthetic corticosteroid that has been used since the late 1970s to treat asthma and allergic rhinitis, available as both an inhaled aerosol for the lungs and a nasal spray for the nose. It belongs to the same family of inhaled corticosteroids as budesonide and fluticasone, but it occupies an unusual niche: its pharmacology makes it relatively gentle on the body’s hormonal systems while still delivering strong anti-inflammatory effects locally. The drug’s story also involves a significant reformulation that changed how much of it actually reaches the lungs, making the modern version meaningfully different from the one prescribed decades ago.

How Flunisolide Works

Like all corticosteroids, flunisolide reduces inflammation by binding to glucocorticoid receptors inside cells. Once bound, the drug-receptor complex moves into the cell nucleus and alters the expression of inflammatory genes, dialing down the production of chemicals that cause swelling, mucus, and airway narrowing. What distinguishes one corticosteroid from another is largely how tightly each binds to those receptors and how the body handles the drug once it’s absorbed.

Flunisolide binds to glucocorticoid receptors with roughly twice the affinity of dexamethasone, a commonly used reference corticosteroid. In laboratory measurements using human tissue, flunisolide showed a relative binding affinity of 190 compared with dexamethasone’s 100.¹ That’s strong enough to be effective in the airways and nasal passages, but it’s actually on the lower end compared to newer inhaled steroids like fluticasone propionate, which bind several times more tightly. This moderate potency turns out to be part of flunisolide’s safety story.

Why Most of It Never Reaches Your Bloodstream

One of flunisolide’s most important characteristics is how quickly the liver breaks it down. When the drug is swallowed (which happens with a large portion of any inhaled dose that lands in the mouth and throat instead of the lungs), it undergoes rapid first-pass metabolism. The liver converts it into a metabolite that has only weak corticosteroid activity.² Studies in healthy volunteers have found that only about 20% of an oral dose of flunisolide makes it into the systemic circulation.³

This rapid breakdown is a feature, not a bug. The goal with any inhaled corticosteroid is to get a therapeutic concentration onto the airway surfaces while minimizing how much active drug circulates through the rest of the body. A drug that the liver chews up quickly will have less opportunity to cause systemic side effects like bone thinning, elevated blood sugar, or suppression of the body’s own cortisol production. Flunisolide’s large volume of distribution and high clearance rate mean that whatever does reach the bloodstream doesn’t linger long.

The Shift from CFC to HFA Inhalers

Flunisolide’s modern history is inseparable from a global environmental policy change. The original metered-dose inhalers used chlorofluorocarbon (CFC) propellants, the same chemicals that were depleting the ozone layer. When international agreements phased out CFC production, pharmaceutical companies had to reformulate their inhalers using hydrofluoroalkane (HFA) propellants instead.⁴ For most drugs, this was a straightforward propellant swap. For flunisolide, the reformulation turned out to be a genuine upgrade.

The HFA version of flunisolide produces an aerosol with much smaller particles than the old CFC version. The mass median aerodynamic diameter dropped from about 3.8 micrometers to roughly 1.2 micrometers.⁵ Smaller particles travel deeper into the lungs and are less likely to slam into the back of the throat, which is where side effects like oral thrush (a fungal infection) and hoarseness originate. The HFA formulation was also designed with a built-in spacer, a short tube attached to the mouthpiece that slows the aerosol plume and gives larger particles time to fall out before reaching the mouth.

The practical result is striking. Lung deposition of the HFA formulation averaged about 40% of the delivered dose when used with the spacer, compared with roughly 17% for the old CFC inhaler used alone.⁶ Meanwhile, throat deposition dropped dramatically. The integrated spacer further improved this ratio, pushing more drug to the lungs and less to the mouth and throat.⁷

Because so much more of the drug reaches its target, the HFA version achieves the same asthma control at roughly one-third the nominal dose of the old CFC formulation.⁸ A lower total dose with better lung targeting means less drug in the throat (fewer local side effects) and less swallowed drug reaching the bloodstream (fewer systemic effects). The built-in spacer also simplifies technique for patients who struggle with the coordination required to fire a metered-dose inhaler and inhale at exactly the right moment.

Soft-Mist and Alternative Delivery Devices

Beyond the standard metered-dose inhaler, researchers have tested flunisolide with other delivery technologies. A soft-mist inhaler device achieved lung deposition of about 45% of the dose, even higher than the HFA inhaler with its spacer, while keeping throat deposition comparable.⁹ Adding a baffle to the device cut throat deposition to under 8%, though it also reduced lung deposition somewhat. These experiments illustrate a broader point about inhaled medications: the device matters as much as the drug. Two patients using the same medication with different inhalers or different technique can end up with very different amounts of drug in their lungs.

How Well It Works for Asthma

Flunisolide has decades of clinical evidence supporting its use in persistent asthma. In adults with severe asthma, high-dose inhaled flunisolide produced lung function improvements comparable to systemic (oral or injected) corticosteroids. One trial found that average forced expiratory volume in one second (a standard measure of how much air you can blow out quickly) increased from 1.6 to 2.3 liters in the inhaled flunisolide group, compared with 1.4 to 2.1 liters in the group receiving systemic steroids, with no statistically significant difference between the two approaches.¹⁰ Getting similar results from an inhaled drug that stays mostly in the lungs, rather than oral prednisone that floods the entire body, is a meaningful clinical advantage.

For children and adolescents already dependent on daily oral steroids, flunisolide has shown a clear steroid-sparing effect. In a controlled trial, every child in the flunisolide group was able to reduce their daily oral steroid dose, compared with just over half in the placebo group.¹¹ Reducing oral steroid exposure in children matters because long-term systemic steroid use carries serious risks to bone density, growth, and metabolic health that inhaled steroids largely avoid.

Flunisolide for Allergic and Perennial Rhinitis

The nasal spray formulation of flunisolide was one of the first intranasal corticosteroids available and has strong evidence for treating year-round nasal symptoms. In an eight-week trial involving patients with perennial rhinitis (the kind triggered by dust mites, pet dander, and other non-seasonal allergens), flunisolide significantly reduced the duration and severity of sneezing, nasal congestion, nose-blowing, and postnasal drip. About three-quarters of patients on flunisolide reported substantial or total control of their symptoms, compared with a quarter of those on placebo.¹²

A separate trial of similar design found comparable results: 75% of flunisolide-treated patients had only mild symptoms or were completely asymptomatic, and two-thirds reported substantial or total symptom control.¹³ Patients also reported improvements in sleep quality and everyday functioning.¹⁴ These trials predate the newer nasal steroids like fluticasone and mometasone, which now dominate the market partly because of once-daily dosing. Flunisolide nasal spray typically requires two doses per day, which can be a practical drawback for some people.

Preventing Nasal Polyp Recurrence

Beyond straightforward rhinitis, flunisolide nasal spray has been studied for preventing nasal polyps from returning after surgical removal. In a year-long placebo-controlled trial, patients who used flunisolide after polypectomy had significantly fewer and smaller recurring polyps than those who used placebo. Sneezing and congestion also improved in the treatment group.¹⁵ Nasal polyps have a frustrating tendency to grow back after surgery, and long-term topical steroid use is one of the few strategies with good evidence for slowing that recurrence.

Effects on the Body’s Cortisol System

A central concern with any corticosteroid, inhaled or otherwise, is whether it suppresses the body’s natural cortisol production. Your adrenal glands produce cortisol in response to signals from the brain (the hypothalamic-pituitary-adrenal axis, or HPA axis), and flooding the body with an external steroid can convince this system to dial down its own output. If that suppression becomes severe, it can leave you unable to mount a normal stress response.

At therapeutic doses, flunisolide appears to have minimal impact on cortisol. One study directly compared flunisolide, fluticasone propionate, and triamcinolone acetonide at their standard inhaled doses and found all three were comparable to placebo in their lack of adrenal-suppressive effects.¹⁶ When doses were pushed higher in a separate study, both flunisolide and fluticasone did cause dose-dependent cortisol suppression, but the suppression was significantly greater with fluticasone.¹⁷ This fits with flunisolide’s pharmacological profile: its moderate receptor binding and rapid metabolism give it a wider gap between the dose needed for lung effects and the dose that starts causing systemic problems.

A review of inhaled corticosteroid safety profiles noted that flunisolide, along with ciclesonide, has reduced effects on the HPA axis and may be a better option for patients where cortisol suppression is a particular concern.¹⁸

Growth in Children

Parents of children with asthma often worry about whether inhaled steroids will stunt growth. Some inhaled corticosteroids have been shown to slow growth velocity slightly during the first year of treatment, though the effect is usually small and does not appear to reduce final adult height in most studies. Flunisolide HFA fares well on this front. A year-long randomized trial in prepubescent children with mild persistent asthma found no difference in growth rate between those taking flunisolide HFA and those on placebo. The flunisolide group grew at an average rate of about 6 centimeters per year, virtually identical to the placebo group’s rate. Bone maturation also progressed at the same pace in both groups.¹⁹

This is reassuring, though it’s worth noting the trial used the HFA formulation at its lower dose. Whether higher doses over longer periods would behave the same way is less certain. As a general rule, doctors prescribing any inhaled steroid for a child aim for the lowest dose that keeps asthma well controlled, regardless of which specific drug is chosen.

Nasal Spray and Mucosal Safety

Long-term nasal spray use raises a reasonable question about what the drug does to the delicate lining of the nose over time. A study that followed patients on flunisolide nasal spray for an extended period and then biopsied the nasal tissue found no histological abnormalities attributable to the drug. In fact, the tissue often looked healthier after treatment, with less swelling and fewer inflammatory cells than before.²⁰

One nuance is that the safety profile of a nasal spray depends not just on the active drug but on the preservatives mixed in. Many nasal steroid formulations contain benzalkonium chloride as a preservative. Animal studies have shown that benzalkonium chloride can cause changes in nasal tissue, including abnormal cell transformation, that do not occur with the steroid alone.²¹ Some formulations of flunisolide nasal spray contain this preservative, while others do not. If you’re using a nasal steroid daily for months or years, it’s worth checking the inactive ingredients list, though the clinical significance of benzalkonium chloride exposure in humans at the concentrations used in nasal sprays remains debated.

In vitro studies have also shown that both flunisolide and the related steroid beclomethasone can reduce the beating frequency of nasal cilia, the tiny hair-like structures that sweep mucus and debris out of the sinuses. The effect was dose-dependent and, unlike the effect seen with the drug’s solvent alone, it was not reversible when the drug was washed away.²² Whether this laboratory finding translates to meaningful impairment of nasal clearance in real patients using standard doses is unclear, but it’s a reason clinicians sometimes emphasize using the lowest effective nasal spray dose.

Drug Interactions Worth Knowing About

Flunisolide is metabolized by the liver’s cytochrome P450 enzyme system. This means it can interact with drugs that strongly inhibit those enzymes, particularly CYP3A4 inhibitors. The most clinically significant interactions occur when inhaled corticosteroids are combined with potent CYP3A4 blockers such as certain antifungal drugs (ketoconazole, itraconazole) or HIV protease inhibitors (ritonavir, cobicistat).²³ These combinations can dramatically slow the breakdown of the corticosteroid, leading to a buildup of active drug in the body and potentially causing Cushing-like symptoms: weight gain, easy bruising, high blood sugar, and suppression of the adrenal glands.

Flunisolide’s rapid first-pass metabolism actually provides some buffer here compared with steroids like fluticasone, whose higher potency and longer half-life make them more susceptible to dangerous accumulation during enzyme-inhibitor interactions. Still, if you’re prescribed an azole antifungal or an HIV protease inhibitor and you’re using any inhaled corticosteroid, your doctor should be aware of the overlap.

Where Flunisolide Fits Among Inhaled Steroids Today

Flunisolide occupies an interesting position in the current inhaled corticosteroid landscape. It’s not the most widely prescribed option; that distinction generally belongs to fluticasone and budesonide, which benefit from massive marketing investment, once-daily dosing options, and extensive pediatric data. But flunisolide’s pharmacological characteristics give it distinct advantages in specific situations. Its rapid metabolism and moderate receptor affinity produce a favorable ratio of local effectiveness to systemic exposure. The HFA reformulation with its built-in spacer solved one of the practical problems with older metered-dose inhalers: the need for add-on spacer devices that patients might forget, lose, or fail to use correctly.

For patients who are sensitive to systemic steroid effects, whether because of existing osteoporosis risk, diabetes, or simply a history of cortisol suppression on other inhaled steroids, flunisolide can be a reasonable alternative worth discussing. It’s also a useful option in settings where cost matters; as an older generic drug, flunisolide is often cheaper than branded newer corticosteroids. The nasal spray formulation competes in a more crowded market where over-the-counter options like fluticasone propionate nasal spray have become dominant, but flunisolide remains a viable choice for perennial rhinitis and post-polypectomy maintenance when other agents aren’t suitable or tolerated.